ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 1772 • 2018 ACR/ARHP Annual Meeting

    Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Javier Loricera2, Genaro Graña Gil3, Gerard Espinosa4, Clara Moriano Morales5, Trinidad Pérez-Sandoval6, Manuel Martín-Martínez6, Elvira Díez6, Maria Dolores Garcia Armario7, Ivan Castellví8, Francisca Sivera9, Jaime Calvo-Alén10, Isabel de la Morena11, Francisco Ortiz-Sanjuán12, José Andrés Román-Ivorra13, Ana Pérez Gómez14, Sergi Heredia15, Carolina Díez16, J Alegre17, Amparo Ybáñez17, Javier Narváez18, Ana Turrión Nieves19, Susana Romero-Yuste20, Alejandro Olivé-Marqués21, Águeda Prior22, Esperanza Martínez7, Ignasi Figueras23, Pilar Trénor24, Carmen Gonzalez Vela25, Diana Prieto Peña26, Monica Calderón Goercke26, José Luis Hernández2, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology Division, Complejo Hospitalario Universitario A Coruña. Spain, La Coruña, Spain, 4Department of Autoimmune Diseases, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 6Rheumatology, Hospital Universitario de León. Spain, León, Spain, 7Rheumatology and Dermatology, Hospital Lluís Alcanyís. Valencia. Spain, Valencia, Spain, 8Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau. Barcelona. Spain, Barcelona, Spain, 9Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 10Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 11Hospital General Universitario de Valencia. Spain, Valencia, Spain, 12Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, 13Hospital La Fe. Valencia. Spain, Valencia, Spain, 14Rheumatology, Hospital Universitario Príncipe de Asturias. Alcalá de Henares. Madrid. Spain, Alcalá de Henares, Madrid, Spain, 15Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, Barcelona, Spain, 16Rheumatology, Hospital de El Bierzo. León. Spain, León, Spain, 17Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 18Rheumatology, Hospital Bellvitge. Barcelona. Spain, Barcelona, Spain, 19Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, 20Hospital de Pontevedra. Spain, Pontevedra, Spain, 21Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 22Rheumatology, Hospital Universitari Germans Trias i Pujol. Barcelona. Spain, Barcelona, Spain, 23Rheumatology and Dermatology, Hospital Bellvitge. Barcelona. Spain, Barcelona, Spain, 24Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 25Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 26Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…
  • Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting

    Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road

    Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…
  • Abstract Number: 1773 • 2018 ACR/ARHP Annual Meeting

    Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Vanesa Calvo-Río2, Rosalía Demetrio-Pablo3, Emma Beltrán4, Marina Mesquida5, Alfredo Adan5, Juan Sánchez Bursón Sr.6, M. Victoria Hernández7, Marisa Hernández8, Elia Valls-Pascual9, L. Martinez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, Jose L. García Serrano13, Norberto Ortego Centeno14, Angel Garcia-Aparicio15, Olga Maiz-Alonso16, Ana Blanco17, Cruz Fernandez-Espartero18, Vega Jovaní19, Diana Peiteado20, Elena Aurrecoechea21, Amalia Sanchez-Andrade22, Enrique Minguez23, Carmen Carrasco-Cubero24, Alejandro Olivé-Marqués25, Esteban Rubio-Romero26, Francisco J. Toyos Sáenz de Miera27, David Diaz-Valle28, Joan Miquel Nolla29, Marcelino Revenga Martínez30, Santos Castañeda31, Jose M Herreras32, Alejandro Fonollosa33, Ignacio Torre-Salaberri34, Esperanza Pato Cour35, Juan Cruz36, Carlos Férnandez Cid37, Miriam García-Arias38, Miguel Angel Caracuel-Ruiz39, Carlos Alberto Montilla-Morales40, Antonio Atanes41, Félix Francisco42, Santos Insua43, Senen González-Suárez44, Fernando Gamero45, Luis Francisco Linares46, Fredeswinda I. Romero-Bueno47, Raquel Almodóvar González48, Julio Vázquez49, A. Javier García-González50, Oscar Ruiz Moreno51, Fernando Jiménez-Zorzo51, Javier Manero51, Santiago Muñoz Fernandez52, Fred Antón Pages53, Myriam Gandía54, Francisco Javier López Longo55, Enrique Raya Álvarez56, Paz Rodríguez-Cundín57, Diana Prieto Peña2, Monica Calderón Goercke2, Enar Pons1, José Luis Hernández3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, 7Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 8Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 9Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 10Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 14Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 15Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 16Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, 17Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 18Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 19Rheumatology, Hospital General Universitario de Alicante. Spain, Alicante, Spain, 20Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 21Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 22Rheumatology, Hospital Lucus Augusti. Lugo. Spain, Lugo, Spain, 23Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, 24Hospital de Mérida. Spain, Mérida, Spain, 25Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 26Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 27Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 28Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 29Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 31Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 32Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 33Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 34Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 35Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 36Rheumatology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 37Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 38Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, 39Rheumatology service, Hospital Universitario Reina Sofía. Córdoba. Spain, Córdoba, Spain, 40Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 41Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 42Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 43Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 44Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 45Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, 46Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 47Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 48Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 49Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, 50Rheumatology, Instituto de Investigación Hospital 12 de octubre. Madrid. Spain, Madrid, Spain, 51Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 52Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, 53Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 54Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 55Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 56Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 57Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain

    Background/Purpose: Uveitis is one of the major causes of disability of Behçet's disease (BD). According to the “Expert panel recommendations” (Ophthalmology. 2014; 121:785-96), anti-TNF therapy…
  • Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting

    Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease

    Ertugrul Cagri Bolek, Alper Sari, Berkan Armagan, Abdulsamet Erden, Levent Kilic, Umut Kalyoncu, Meryem Asli Tuncer, Sedat Kiraz and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey

    Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…
  • Abstract Number: 1778 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease

    Su Jin Choi1, Doo-Ho Lim2, Ji Seon Oh1, Seokchan Hong1, Yong-Gil Kim1, Chang Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)

    Background/Purpose: Systemic vasculitis is one of the major manifestations of Behcet’s disease (BD). Takayasu’s arteritis (TA) is a chronic vasculitis that primarily affects the aorta…
  • Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients

    Gul Guzelant1, Yilmaz Ozyazgan2, Cem Mat3, Vedat Hamuryudan1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…
  • Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting

    Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Lucia C. Domínguez-Casas1, Nuria Vegas-Revenga1, Vanesa Calvo-Río1, Natalia Palmou Fontana2, Ricardo Blanco3, Javier Loricera1, MC Gonzalez-Vela4, Emma Beltrán5, Lucía Martínez Costa6, Elia Valls Pascual6, Marisa Hernández Garfella5, Antonio Atanes7, Miguel Cordero Coma8, Joan Miquel Nolla Solé9, Carmen Carrasco Cubero10, Enar Pons11 and Miguel Angel González-Gay2, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 5Hospital General Universitario de Valencia, Valencia, Spain, 6Hospital Peset, Valencia, Spain, 7Hospital Universitario de A Coruña, A Coruña, Spain, 8Hospital de León, León, Spain, 9Hospital Universitari de Bellvitge, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain

    Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…
  • Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting

    Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Lucia C. Domínguez-Casas1, Nuria Vegas-Revenga1, Vanesa Calvo-Río1, Emma Beltrán2, Juan Sánchez-Burson3, Marina Mesquida4, Alfredo Adán4, M Victoria Hernández4, Javier López-Longo5, Marisa Hernández Garfella2, Elia Valls Pascual6, Lucía Martínez Costa6, Agustí Sellas-Fernandez7, José L. García-Serrano8, José-Luis Callejas-Rubio8, Norberto Ortego8, José M. Herreras9, Alejandro Fonollosa10, Olga Maíz11, Ana Blanco12, Ignacio Torre13, C. Fernandez-Espartero14, V. Jovani15, D. Peiteado Lopez16, David Díaz Valle17, Esperanza Pato17, J. Cruz18, C. Fernandez-Cid18, Elena Aurrecoechea19, M. García20, Miguel A. Caracuel21, Antonio Atanes22, F. Francisco23, Santos Insúa24, S. Gonzalez-Suárez25, A. Sánchez-Andrade26, L. Linares27, F. Romero-Bueno28, A. J. García29, R. Almodovar30, Enrique Mínguez31, Carmen Carrasco Cubero32, E. Raya Álvarez8, M. Alcalde-Villar33, C. Fernández-Carbadillo34, FA. Pagés35, MC Gonzalez-Vela36, Rosalia Demetrio37, Enar Pons37, Jose L. Hernández38, Miguel Angel González-Gay39 and Ricardo Blanco40, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital General Universitario de Valencia, Valencia, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital Gregorio Marañón, Madrid, Spain, 6Hospital Peset, Valencia, Spain, 7Hospital Vall d´Hebron, Barcelona, Spain, 8Hospital San Cecilio, Granada, Spain, 9Hospital Universitario IOBA, Valladolid, Spain, 10Hospital de Cruces, Bilbao, Spain, 11Hospital Donosti, San Sebastian, Spain, 12Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 13Hospital Basurto, Bilbao, Spain, 14Hospital Universitario de Móstoles, Madrid, Spain, 15Hospital General Alicante, Alicante, Spain, 16Hospital Universitario La Paz, Madrid, Spain, 17Hospital Clínico San Carlos, Madrid, Spain, 18Hospital Pontevedra, Pontevedra, Spain, 19Hospital Sierrallana, Torrelavega, Spain, 20Hospital La Princesa, Madrid, Spain, 21Hospital Córdoba, Córdoba, Spain, 22Hospital Universitario de A Coruña, A Coruña, Spain, 23Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, 24Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 25Hospital Cabueñes, Gijón, Spain, 26Hospital Lucus Augusti, Lugo, Spain, 27Hospital Arrixaca, Murcia, Spain, 28Fundación Jiménez Díaz, Madrid, Spain, 29Hospital 12 de Octubre, Madrid, Spain, 30Hospital Universitario Fundación Alcorcón, Madrid, Spain, 31Hospital Clínico Zaragoza, Zaragoza, Spain, 32Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 33Hospital Severo Ochoa, Madrid, Spain, 34Hospital General Universitario de Elda, Alicante, Spain, 35Complejo Asistencial de Palencia, Palencia, Spain, 36Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 37Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 38Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 39Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa, 40Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…
  • Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting

    Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Nuria Vegas-Revenga1, Lucia C. Domínguez-Casas1, Vanesa Calvo-Río1, Emma Beltrán2, Juan Sánchez-Burson3, Marina Mesquida4, Alfredo Adán4, M Victoria Hernández4, Marisa Hernández Garfella2, Elia Valls Pascual5, Lucía Martínez Costa5, Agustí Sellas-Fernandez6, Miguel Cordero Coma7, Manuel Díaz-Llopis8, Roberto Gallego8, David Salom8, Norberto Ortego9, José L. García-Serrano9, José-Luis Callejas-Rubio9, José M. Herreras10, Ángel M García-Aparicio11, Olga Maíz12, Ana Blanco13, Ignacio Torre14, David Díaz Valle15, Esperanza Pato15, Elena Aurrecoechea16, Miguel A. Caracuel17, Fernando Gamero18, Enrique Mínguez19, Carmen Carrasco Cubero20, Alejandro Olive21, Julio Vázquez22, Oscar Ruiz Moreno23, Fernando Jiménez-Zorzo24, Javier Manero24, Myriam Gandia Martinez25, Esteban Rubio-Romero26, F. Javier Toyos-Sáenz de Miera27, Javier López-Longo28, JM Nolla29, Marcelino Revenga30, Rosalia Demetrio31, Enar Pons31, Miguel Angel González-Gay1 and Ricardo Blanco32, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital General Universitario de Valencia, Valencia, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital Peset, Valencia, Spain, 6Hospital Vall d´Hebron, Barcelona, Spain, 7Hospital de León, León, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital San Cecilio, Granada, Spain, 10Hospital Universitario IOBA, Valladolid, Spain, 11Hospital Donosti, San Sebastián, Spain, 12Hospital Donosti, San Sebastian, Spain, 13Ophthalmology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 14Hospital Basurto, Bilbao, Spain, 15Hospital Clínico San Carlos, Madrid, Spain, 16Hospital Sierrallana, Torrelavega, Spain, 17Hospital Córdoba, Córdoba, Spain, 18Hospital San Pedro Alcántara, Cácerer, Spain, 19Hospital Clínico Zaragoza, Zaragoza, Spain, 20Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 21Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 22Hospital de Ferrol, A Coruña, Spain, 23Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 24Hospital Miguel Servet, Zaragoza, Spain, 25Hospital Puerta del Mar, Cádiz, Spain, 26Hospital Universitario Virgen del Rocío, Sevilla, Spain, 27Hospital Universitario Virgen Macarena, Sevilla, Spain, 28Hospital Gregorio Marañón, Madrid, Spain, 29Hospital Universitari de Bellvitge, Barcelona, Spain, 30Hospital Universitario Ramón y Cajal, Madrid, Spain, 31Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria., Santander, Spain, 32Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…
  • Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting

    Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Javier Loricera1, Nuria Vegas-Revenga1, Lucia C. Domínguez-Casas1, Jose L. Hernández2, Clara Moriano3, Maria Dolores García-Armario4, Iván Castelvi5, Francisca Sivera6, Jaime Calvo-Alen7, Isabel de la Morena8, Francisco Ortiz-Sanjuán9, José Andrés Román-Ivorra9, Ana Pérez-Gómez10, MC Gonzalez-Vela11, Miguel Angel González-Gay1 and Ricardo Blanco12, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Complejo Asistencial Universitario de León, León, Spain, 4Hospital de Xàtiva, Xàtiva, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital General Universitario de Elda, Elda, Spain, 7Hospital Universitario Araba, Vitoria, Spain, 8Hospital General Universitario de Valencia, Valencia, Spain, 9Hospital La Fe, Valencia, Spain, 10Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 11Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 12Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…
  • Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting

    Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients

    Pelin Ünsal1, Pamir Cerci2, Şükrü Alper Açıkgöz2, Göksal Keskin2 and Ümit Ölmez2, 1Ankara University School of Medicine, Ankara, Turkey, 2Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey

    Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…
  • Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting

    Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome

    Hasan Tuzun1, Gul Guzelant2, Ozkan Demirhan3, Buge Oz4, Izzet Fresko2, Vedat Hamuryudan2, Hasan Yazici2 and Emire Seyahi2, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey

    Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…
  • Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting

    Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease

    Hirotoshi Kikuchi1, Tetsuji Sawada2, Masato Okada3, Mitsuhiro Takeno4, Masataka Kuwana4, Yoshiaki Ishigatsubo5, Izumi Kawachi6, Hideki Mochizuki7, Susumu Kusunoki8 and Shunsei Hirohata9, 1Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 2Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, 3Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 6Department of Neurology, Niigata University Medical and Dental Hospital, Niigata, Japan, 7Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan, 8Department of Neurology, Kinki University School of Medicine, Osaka, Japan, 9Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

    Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…
  • Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting

    Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment

    Petros P Sfikakis1, Aikaterini Arida1, Stylianos Panopoulos2, Kalliopi Fragkiadaki2, George Pentazos3, Katerina Laskari3, Maria Tektonidou1 and Nikos Markomichelakis2, 1First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, 2First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, 3Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece

    Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
  • Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting

    Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide

    Mert Gurcan1, Sinem Nihal Esatoglu1, Vedat Hamuryudan1, Caner Saygin2, Didem Saygin3, Serdal Ugurlu4, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko1, Sebahattin Yurdakul1, Hasan Yazici1 and Gulen Hatemi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, 3Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, 4Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

     Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology